Treatment of Behçet's syndrome

Rheumatology

Volumn 45, Issue 3, 2006, Pages 245-247

  Barnes, C G ^a,b  

^a ROYAL LONDON HOSPITAL   (United Kingdom)

^b NONE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA INTERFERON; ANALGESIC AGENT; ANTIINFLAMMATORY AGENT; AZATHIOPRINE; COLCHICINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; ETANERCEPT; INFLIXIMAB; METHYLPREDNISOLONE; METHYLPREDNISOLONE ACETATE; SALAZOSULFAPYRIDINE; THALIDOMIDE; TRIAMCINOLONE; GLUCOCORTICOID;

ARTHRALGIA; ARTHRITIS; BEHCET DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE CLASSIFICATION; DISEASE SEVERITY; EDITORIAL; ERYTHEMA NODOSUM; HUMAN; MOUTH ULCER; NEUROTOXICITY; PRIORITY JOURNAL; RETINA VASCULITIS; TERATOGENICITY; THROMBOPHLEBITIS; UVEITIS; NOTE;

BEHCET SYNDROME; GLUCOCORTICOIDS; HUMANS;

EID: 33644854604     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kei257     Document Type: Editorial

References (35)

1. Mat C, Yurdakul S, Uysal S et al. A double-blind trial of depot corticosteroids in Behçet's Syndrome. Rheumatology 2005;44.
2. Yazici H, Fresko I, Tunc R, Melikoǧlu M. Behcet's syndrome: pathogenesis, clinical manifestations and treatment. In: Ball G, Bridges SL, eds. Vasculitis. New York: Oxford University Press, 2002:406-32.
3. Mason RM, Barnes CG. Behçet's syndrome with arthritis. Ann Rheum Dis 1969;28:95-103.
4. Dilsen N, Konice M, Ardal O. Our diagnostic criteria of Behçet's disease - an overview. In: Lehner T, Barnes CG, eds. Recent advances in Behçet's disease. International Congress and Symposium Series, no. 103. London: Royal Society of Medicine Service, 1986:177-80.
5. O'Duffy JD. Suggested criteria for diagnosis of Behçet's Disease. J Rheumatol 1974;1(Suppl 1):aBstract 32:18.
6. Mizushima Y. Recent research into Behçet's disease in Japan. Int J Tiss React 1988;10:59-65.
7. International Study Group for Behçet's Disease. Criteria for diagnosis of Behcet's disease. Lancet 1990;335:1078-80.
8. Alpsoy E. Behçet's disease: Treatment of mucocutaneous lesions. Clin Exp Rheumatol 2005;23:532-9.
9. Yazici H, Tuzun Y, Pazarli H et al. Influence of age of onset and patient's sex on the prevalence and severity of manifestations of Behçet's syndrome. Ann Rheum Dis 1984;43:783-9.
10. Yurdakul S, Mat C, Tuzun Y et al. A double blind trial of colchicine in Behçet's syndrome. Ann Rheum Dis 2001;44:2686-92.
11. Yazici H, Pazarli H, Barnes CG et al. A controlled trial of azathioprine in Behçet's syndrome. N Engl J Med 1990;322:139-41.
12. Masuda K, Nakajima A, Urayama A, Nakae K, Kogure M, Inaba G. Double-masked trial of cyclosporine versus colchicine and long-term open study of cyclosporine in Behçet's disease. Lancet 1989;20:1093-6.
13. Avci O, Gurler N, Gunes AT. Efficacy of cyclosporine on mucocutaneous manifestations of Behçet's disease. J Am Acad Dermatol 1997;36:796-7.
14. Zouboulis CC, Orfanos CE. Treatment of Adamantiades-Behçet disease with systemic interferon alpha. Arch Dermatol 1998;134:1010-6.
15. Alpsoy E, Durusoy C, Yilmaz E et al. Interferon alpha-2a in the treatment of Behçet's disease. A randomized placebo-controlled and double blind study. Arch Dermatol 2002;138:467-71.
16. Hamuryudan V, Mat C, Saip S et al. Thalidomide in the treatment of the mucocutaneous lesions of the Behçet syndrome. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1998; 128:443-50.
17. Ochonisky S, Verroust J, Bastuji-Garin S, Gheradi R, Revuz J. Thalidomide neuropathy incidence and clinico-electrophysiologic findings in 42 patients. Arch Dermatol 1994;130:66-9.
18. Robertson LP, Hickling P. Treatment of recalcitrant orogenital ulceration of Behçet's syndrome with infliximab. Rheumatology 2001;40:473-4.
19. Goossens PH, Verburg RJ, Breedveld FC. Remission of Behçet's syndrome with tumour necrosis factor alpha blocking. Ann Rheum Dis 2001;63:744-5.
20. Melikoǧlu M, Fresco I, Mat C et al. Short-term trial of etanercept in Behçet's disease: A double blind, placebo controlled study. J Rheumatol 2005;32:98-105.
21. Hamuryudan V, Moral F, Yurdakul S et al. Systemic interferon alpha 2b treatment in Behçet's syndrome. J Rheumatol 1994; 21:1098-100.
22. Kötter I, Vonthein R, Zierhut M et al. Differential efficacy of human recombinant interferon-alpha 2a on ocular and extraocular manifestations of Behçet's disease: Results of an open 4-center trial. Semin Arthritis Rheum 2004;33:311-9.
23. Ozyazgan Y, Yurdakul S, Yazici H et al. Low dose cyclosporine A versus pulsed cyclophosphamide in Behçet's syndrome: A single masked trial. Br J Ophthalmol 1992;76:241-3.
24. BenEzra D, Cohen E, Chajek T et al. Evaluation of conventional therapy versus cyclosporine A in Behçet's syndrome. Transplant Proc 1988;20:136-43.
25. Kötter I, Zierhut M, Eckstein AK et al. Human recombinant interferon alfa-2a for treatment of Behçet's disease with sight threatening posterior or panuveitis. Br J Ophthalmol 2003;87: 423-31.
26. Kötter I, Günaydin I, Zierhut M, Stübiger N. The use of interferon alpha in Behçet disease: Review of the literature. Semin Arthritis Rheum 2004;33:320-35.
27. Hamuryudan V, Ozyazgan Y, Hizli N et al. Azathioprine in Behçet's syndrome: Effects on long-term prognosis. Arthritis Rheum 1997;40:769-74.
28. Tugal-Tutkun I, Mudun A, Urgancioglu M et al. Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine and corticosteroids in Behçet's disease: An open-label trial. Arthritis Rheum 2005;52:2478-84.
29. Hampton KK, Chamberlain MA, Menon DK, Davies JA. Coagulation and fibrinolytic activity in Behçet's disease. Thromb Haemost 1991;66:292-4.
30. Mader R, Ziv M, Adawi M, Mader R, Lavi I. Thrombophilic factors and their relation to thromboembolic and other clinical manifestations in Behçet's disease. J Rheumatol 1999;26:2404-8.
31. Efthimiou J, Johnston C, Spiro SG, Turner-Warwick M. Pulmonary disease in Behçet's syndrome. Quart J Med 1986;58:259-80.
32. Hamuryudan V, Er T, Seyahi E et al. Pulmonary artery aneurysms in Behçet syndrome. Am J Med 2004;117:867-70.
33. Diri E, Mat C, Hamuryudan V, Yurdakul S, Hizli N, Yazici H. Papulopustular skin lesions are seen more frequently in patients with Behçet's syndrome who have arthritis: A controlled and masked study. Ann Rheum Dis 2001;60:1074-76.
34. Tunc R, Keyman E, Melikoǧlu M, Fresko I, Yazici H. Target organ associations in Turkish patients with Behçet's disease: A cross sectional study by exploratory factor analysis. J Rheumatol 2002;29:2393-6.
35. Hatemi G, Bahar H, Uysal S et al. The pustular skin lesion of Behçet's syndrome are not sterile. Ann Rheum Dis 2004;63:1450-2.